AC Immune (ACIU) Current Leases (2019 - 2025)
AC Immune (ACIU) reported Current Leases of $1.1 million for Q4 2025, down 8.98% year-over-year from $1.2 million in Q4 2024, and down 18.4% on a QoQ basis from $1.3 million in Q3 2025.
AC Immune (ACIU) has 7 years of Current Leases data on file, last reported at $1.1 million in Q4 2025.
- Quarterly Current Leases fell 8.98% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 million (down 8.98% YoY) and the FY2025 annual result came in at $1.0 million, down 12.26% from the prior year.
- Current Leases retreated to $1.1 million in Q4 2025 per ACIU's latest filing, from $1.3 million in the prior quarter.
- Across five years, Current Leases topped out at $757.6 million in Q4 2023 and bottomed at $568836.0 in Q4 2022.
- The 5-year median for Current Leases is $933508.2 (2024), against an average of $156.5 million.
- The widest annual swing landed in 2021, when Current Leases surged 137655.92%; it then plunged 99.91% in 2022.
- Tracing ACIU's Current Leases over 5 years: stood at $618.2 million in 2021, then sank by 99.91% to $568836.0 in 2022, then surged by 133081.13% to $757.6 million in 2023, then tumbled by 99.85% to $1.2 million in 2024, then decreased by 8.98% to $1.1 million in 2025.
- Per Business Quant, the three latest ACIU Current Leases figures stand at $1.1 million (Q4 2025), $1.3 million (Q3 2025), and $1.3 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 83,991.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 720.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 45.66 Mn |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.07 Mn |
| Sep 30, 2025 | 1.31 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Mar 31, 2025 | 1.15 Mn |
| Dec 31, 2024 | 1.17 Mn |
| Sep 30, 2024 | 801,019.83 |
| Jun 30, 2024 | 759,680.13 |
| Mar 31, 2024 | 769,898.52 |
| Dec 31, 2023 | 757.58 Mn |
| Sep 30, 2023 | 628,344.67 |
| Jun 30, 2023 | 615,033.08 |
| Mar 31, 2023 | 595,720.58 |
| Dec 31, 2022 | 568,836.01 |
| Sep 30, 2022 | 601,600.30 |
| Jun 30, 2022 | 599,095.06 |
| Mar 31, 2022 | 620,449.20 |
| Dec 31, 2021 | 618.17 Mn |
| Sep 30, 2021 | 628.43 Mn |
| Jun 30, 2021 | 626.19 Mn |
| Mar 31, 2021 | 487.77 Mn |
| Dec 31, 2020 | 490,026.94 |
| Sep 30, 2020 | 479,087.18 |
| Jun 30, 2020 | 454,561.60 |
| Mar 31, 2020 | 449,723.27 |
| Dec 31, 2019 | 446,589.56 |
| Sep 30, 2019 | 432,369.28 |
| Jun 30, 2019 | 418.87 |
| Mar 31, 2019 | 417,690.01 |